December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

148.06 +4.62 (+3.22%)
Streaming Delayed Price Updated: 2:30 PM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
77 78 Next >
News headline image
Worried About a Market Crash? These 3 Stocks Beat the S&P 500 in 2008 and 2022 ↗
These stocks can be safe-haven investments to hide out in amid market turmoil. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? ↗
One offers concentrated exposure to 29 pharma giants with lower volatility, while the other provides broader diversification across 251 biotech companies at a cheaper cost. 
Via The Motley Fool
Topics ETFs
News headline image
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited. ↗
The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs. 
Via The Motley Fool
Gilead Sciences (NASDAQ:GILD) Posts Q2 Beat but Stock Slips on Full-Year Guidance ↗
Via Chartmill
Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors ↗
Via Chartmill
News headline image
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?
Over the last six months, Gilead Sciences’s shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark contrast to the S&P 500’s 13.1% gain.... 
Via StockStory
Topics Stocks
Global Drugmakers Earmark Billions to Ramp Up Their US Footprint
Via Investor Brand Network
Topics World Trade
News headline image
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript ↗
Enrollment completed six months early; $1.5B cash runway into 2029. 
Via The Motley Fool
Topics Earnings
News headline image
KLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’ ↗
Joshua Brown chose Snowflake Inc., while Rob Sechan picked KLA Corp and Brian Belski recommended Gilead Sciences. Joseph Terranova went for Airbnb. 
Via Benzinga
News headline image
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today ↗
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.04% on an annualized basis producing an average annual return of 11.31%. Currently, Gilead Sciences has a market... 
Via Benzinga
News headline image
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment,... 
Via StockStory
Topics Earnings
News headline image
Compugen (CGEN) Q2 2026 Earnings Call Transcript ↗
COM701 interim data expected in Q1 2027 as cash runway extends into 2029. 
Via The Motley Fool
Topics Earnings
News headline image
3 Healthcare Stocks with Open Questions
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
News headline image
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026? ↗
XLV's lower costs and broader holdings delivered 30% more growth over five years, while BBH's concentrated biotech focus offers higher single-stock upside. 
Via The Motley Fool
Topics ETFs
News headline image
GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) announced better-than-expected revenue in Q2 CY2026, with sales up 10.2% year on year to $7.80 billio... 
Via StockStory
News headline image
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Q2 Earnings Call Highlights ↗
Gilead Sciences (NASDAQ:GILD) reported second-quarter 2026 base business sales growth of 10% year over year to $7.6 billion, supported by HIV treatments and prevention products, Trodelvy in oncology... 
Via MarketBeat
Topics Earnings
News headline image
Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.2% year on yea... 
Via StockStory
News headline image
Why Gilead's High-Profile HIV Drug Might Have To Play Catch-Up ↗
Gilead Sciences narrowly beat sales expectations for HIV PrEP drug, Yeztugo. 
Via Investor's Business Daily
News headline image
SpaceX Could Swing $204 Billion After Earnings ↗
Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfizer and 5.15% for Amgen and Gilead Sciences. 
Via Benzinga
News headline image
Merck Spotlights Weekly HIV Treatment, Monthly PrEP as $5B Growth Opportunity ↗
Merck & Co., Inc. (NYSE:MRK) outlined its HIV treatment and prevention strategy at an investor event following the International AIDS Conference, highlighting Phase III results for a once-weekly oral... 
Via MarketBeat
News headline image
Compugen Q2 Earnings Call Highlights ↗
Compugen (NASDAQ:CGEN) said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash... 
Via MarketBeat
Topics Earnings
News headline image
Eli Lilly Could Swing Over $76 Billion In Value After Earnings ↗
Earnings season is approaching, and Benzinga Pro has a list of top stocks to watch. Gilead Sciences and Uber Technologies are expected to have significant market moves based on their upcoming earnings... 
Via Benzinga
News headline image
Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday after market hours. Here’s what to expect. Gilead Sciences be... 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Large-Cap Stocks for Long-Term Investors and 1 Facing Challenges
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit... 
Via StockStory
News headline image
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial ↗
Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy. 
Via Benzinga
News headline image
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees ↗
VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors. 
Via The Motley Fool
Topics ETFs
News headline image
Global Prophylactic HIV Drug Market Growing at 7.8% CAGR Through 2034 ↗
According to a new report from Intel Market Research, the global Prophylactic HIV Drug Market was valued at USD 3.45 billion in 2025 and is projected to re 
Via Talk Markets
News headline image
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? ↗
VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield. 
Via The Motley Fool
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
77 78 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.